NCT03395002View on ClinicalTrials.gov

Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

March 22, 2018

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
COPD
Interventions
DRUG

Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder

Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.

DRUG

Tiotropium 18 mcg Inhalation Powder

Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.

DRUG

Salmeterol/Fluticasone 50/500 mcg Inhalation Powder

Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days

Trial Locations (2)

Unknown

Cukurova University Faculty of Medicine, Chest Diseases Department, Adana

Health Sciences University, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Neutec Ar-Ge San ve Tic A.Ş

INDUSTRY

NCT03395002 - Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment | Biotech Hunter | Biotech Hunter